KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) EPS (Weighted Average and Diluted) (2023 - 2025)

Biocryst Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at $1.13 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 969.23% year-over-year to $1.13; the TTM value through Dec 2025 reached $1.21, up 381.4%, while the annual FY2025 figure was $1.21, 381.4% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $1.13 in Q4 2025 per BCRX's latest filing, up from $0.06 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.13 in Q4 2025 to a low of -$0.89 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 3 years is -$0.01, with a median of -$0.06 recorded in 2024.
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 85.34% in 2024, then surged 969.23% in 2025.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.89 in 2023, then surged by 85.34% to -$0.13 in 2024, then surged by 969.23% to $1.13 in 2025.
  • Per Business Quant, the three most recent readings for BCRX's EPS (Weighted Average and Diluted) are $1.13 (Q4 2025), $0.06 (Q3 2025), and $0.02 (Q2 2025).